Immunohistochemistry testing was performed on tumors from all affected individuals with colon cancers as a first step (before the referral to the high-risk clinic) to test for the presence of MMR proteins and select individuals at high risk for LS. This evidence concerns the gene MRC1 and colonic neoplasm.